MR-guided SBRT boost for patients with locally advanced or recurrent gynecological cancers ineligible for brachytherapy: feasibility and early clinical experience
Authors:
- Indrawati HadiIHIndrawati Hadi
- Chukwuka EzeCEChukwuka Eze
- Stephan SchöneckerSSStephan Schönecker
- Rieke von BestenbostelRBRieke von Bestenbostel
- Paul RogowskiPRPaul Rogowski
- Lukas NiererLNLukas Nierer
- Raphael BodensohnRBRaphael Bodensohn
- Michael ReinerMRMichael Reiner
- Guillaume LandryGLGuillaume Landry
- Claus BelkaCBClaus Belka
- Maximilian NiyaziMNMaximilian Niyazi
- Stefanie CorradiniSCStefanie Corradini
Open Access
- 15 January 2022
- journal article
- research article
- Published by Springer Nature in Radiation Oncology
- Vol. 17 (1) , 1-9
Abstract
Background and purpose: Chemoradiotherapy (CRT) followed by a brachytherapy (BT) boost is the standard of care for patients with locally advanced or recurrent gynecological cancer (LARGC). However, not every patient is suitable for BT. Therefore, we investigated the feasibility of an MR-guided SBRT boost (MRg-SBRT boost) following CRT of the pelvis. Material and methods: Ten patients with LARGC were analyzed retrospectively. The patients were not suitable for BT due to extensive infiltration of the pelvic wall (10%), other adjacent organs (30%), or both (50%), or ineligibility for anesthesia (10%). Online-adaptive treatment planning was performed to control for interfractional anatomical changes. Treatment parameters and toxicity were evaluated to assess the feasibility of MRg-SBRT boost. Results: MRg-SBRT boost was delivered to a median total dose of 21.0 Gy in 4 fractions. The median optimized PTV (PTVopt) size was 43.5ccm. The median cumulative dose of 73.6Gy10 was delivered to PTVopt. The cumulative median D2ccm of the rectum was 63.7 Gy; bladder 72.2 Gy; sigmoid 65.8 Gy; bowel 59.9 Gy (EQD23). The median overall treatment time/fraction was 77 min, including the adaptive workflow in 100% of fractions. The median duration of the entire treatment was 50 days. After a median follow-up of 9 months, we observed no CTCAE ≥ °II toxicities. Conclusion: These early results report the feasibility of an MRg-SBRT boost approach in patients with LARGC, who were not candidates for BT. When classical BT-OAR constraints are followed, the therapy was well tolerated. Long-term follow-up is needed to validate the results.Keywords
This publication has 30 references indexed in Scilit:
- Stereotactic Body Radiotherapy as an Alternative to Brachytherapy in Gynecologic CancerBioMed Research International, 2013
- Brachytherapy-emulating robotic radiosurgery in patients with cervical carcinomaRadiation Oncology, 2013
- Radiotherapy in marginal zone lymphomaRadiation Oncology, 2013
- Use of Image-Guided Stereotactic Body Radiation Therapy in Lieu of Intracavitary Brachytherapy for the Treatment of Inoperable Endometrial NeoplasiaInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2013
- Impact of 3D image-based PDR brachytherapy on outcome of patients treated for cervix carcinoma in France: Results of the French STIC prospective studyRadiotherapy and Oncology, 2012
- CyberKnife Boost for Patients with Cervical Cancer Unable to Undergo BrachytherapyFrontiers in Oncology, 2012
- Clinical outcome of protocol based image (MRI) guided adaptive brachytherapy combined with 3D conformal radiotherapy with or without chemotherapy in patients with locally advanced cervical cancerRadiotherapy and Oncology, 2011
- Stereotactic body radiotherapy (SBRT): Technological innovation and application in gynecologic oncologyGynecologic Oncology, 2011
- External Beam Boost for Cancer of the Cervix Uteri When Intracavitary Therapy Cannot Be PerformedInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2008
- Radiation Therapy of Pelvic Recurrence after Radical Hysterectomy for Cervical CarcinomaGynecologic Oncology, 1998